China Biotech Weekly #7: Pentagon Adds WuXi to 1260H List — Then Withdraws It Hours Later

This Week's Top Takeaway

The US Department of Defense published an updated Section 1260H list of "Chinese military companies" on February 13, 2026, that included WuXi AppTec (药明康德) for the first time — then withdrew the entire list within approximately one hour. The withdrawal letter, signed by the acting director of the Pentagon's privacy, civil liberties and transparency directorate, provided no explanation. This is the single most consequential BIOSECURE development since the Act's enactment.

What the Withdrawal Means (and Doesn't Mean)

What it means:

DoD had internally determined that WuXi AppTec meets the criteria for 1260H designation
The designation process was advanced enough to reach Federal Register publication
The withdrawal was administrative, not substantive — no official stated that WuXi does not merit listing
Political and trade considerations likely influenced the withdrawal timing

What it doesn't mean:

The withdrawal does NOT mean WuXi is "safe" from future designation
It does NOT affect WuXi's potential Category B BCC designation through the OMB process
It does NOT change the congressional recommendation from December 18, 2025
It does NOT provide any compliance safe harbor for companies with WuXi contracts

The most likely interpretation: The withdrawal reflects inter-agency coordination issues or trade negotiation considerations, not a determination that WuXi doesn't meet 1260H criteria. Compliance teams should plan for the possibility that WuXi reappears on the next 1260H update.

BIOSECURE Watch

Status: 🔴 Urgent Development

Pentagon published then withdrew 1260H list update including WuXi AppTec
Congressional pressure on DoD to add WuXi remains active (December 18 letter)
OMB BCC list process running in parallel — December 2026 deadline unchanged
SEC disclosure count now approximately 10 companies

WuXi share price: Dropped ~8% on Hong Kong exchange during the brief period the list was published, then partially recovered after withdrawal. The market priced WuXi's BIOSECURE risk as significant but not yet certain.

Takeaways for BD Teams

"Withdrawn" is not "cleared." WuXi's presence on the draft 1260H list — even briefly — confirms that DoD assessed WuXi as meeting military company criteria. Your compliance planning should account for re-listing as a realistic scenario.

The compliance window may be shorter than expected. If WuXi appears on the next 1260H update, Category A designation follows — with no grandfathering. Organizations that treated the withdrawal as an all-clear will be caught unprepared.

Track both the 1260H list AND the OMB Category B process. WuXi could become a BCC through either pathway. The 1260H route is faster (60 days after FAR, no grandfathering). The OMB route is slower but has its own 12-month clock.

This event should accelerate your CDMO contingency planning. If you haven't started evaluating alternative CDMOs for WuXi-dependent programs, today is the day. Not because designation is certain — but because the cost of being wrong is 18-24 months of delayed clinical development.

China Biotech Weekly is published every Thursday. For questions, tips, or deal intelligence, reach out at antony@chinabiointel.com. — Antony Tan